Our medicines
Update to voluntary recall of Eliquis® (apixaban) 5 mg tablets (#HN0063)

Recall to retail/dispensing level only

On June 10, Bristol Myers Squibb announced a voluntary recall of one lot (#HN0063) of Eliquis 5 mg tablets. This lot was distributed nationwide in the U.S. to wholesalers and retail pharmacies in February 2017. Bristol Myers Squibb is taking this precautionary measure based on a single customer complaint that a bottle labeled as Eliquis 5 mg was found to contain Eliquis 2.5 mg tablets. No other lots are impacted by this recall.

This recall is to the retail/dispensing level and not to the consumer level. This recall is under way and is currently being executed. The recall is being conducted with the knowledge of the U.S. Food and Drug Administration. Patients should not stop taking Eliquis without consulting with their physician

Please see Eliquis U.S. Full Prescribing Information, including Boxed WARNINGS.

For any customer or patient questions, please call:

General and Medical Inquiries

Bristol Myers Squibb Customer Information Center

Recall Logistics

FedEx Supply Chain

Reimbursement/Replacement Process

FedEx Supply Chain

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Additional Bristol Myers Squibb contacts:

Media: Ken Dominski, 609-252-5251, ken.dominski@bms.com
InvestorsTim Power, 609-252-7509, timothy.power@bms.com